JP2014524480A5 - - Google Patents

Info

Publication number

JP2014524480A5

JP2014524480A5 JP2014527329A JP2014527329A JP2014524480A5 JP 2014524480 A5 JP2014524480 A5 JP 2014524480A5 JP 2014527329 A JP2014527329 A JP 2014527329A JP 2014527329 A JP2014527329 A JP 2014527329A JP 2014524480 A5 JP2014524480 A5 JP 2014524480A5

Authority

JP

Japan

Prior art keywords

pharmaceutical formulation

active agent

formulation

pharmaceutical

derivative

Prior art date

2012-08-24

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 24
• 239000013543 active substance Substances 0.000 claims 16
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 14
• 239000000825 pharmaceutical preparation Substances 0.000 claims 13
• 239000003814 drug Substances 0.000 claims 10
• 229940124597 therapeutic agent Drugs 0.000 claims 9
• 238000009472 formulation Methods 0.000 claims 8
• 239000000203 mixture Substances 0.000 claims 8
• 239000011780 sodium chloride Substances 0.000 claims 7
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
• 102000004169 proteins and genes Human genes 0.000 claims 6
• 108090000623 proteins and genes Proteins 0.000 claims 6
• 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 5
• DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 5
• 102100040918 Pro-glucagon Human genes 0.000 claims 5
• 150000001413 amino acids Chemical group 0.000 claims 5
• 229940123232 Glucagon receptor agonist Drugs 0.000 claims 4
• 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims 4
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 4
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 4
• 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 claims 4
• 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 4
• 229940044601 receptor agonist Drugs 0.000 claims 4
• 239000000018 receptor agonist Substances 0.000 claims 4
• 102000004877 Insulin Human genes 0.000 claims 3
• 108090001061 Insulin Proteins 0.000 claims 3
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 3
• 229940125396 insulin Drugs 0.000 claims 3
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 2
• 101000666868 Homo sapiens Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 claims 2
• 102100038286 Vasoactive intestinal polypeptide receptor 2 Human genes 0.000 claims 2
• 239000000556 agonist Substances 0.000 claims 2
• 239000001110 calcium chloride Substances 0.000 claims 2
• 229910001628 calcium chloride Inorganic materials 0.000 claims 2
• 235000011148 calcium chloride Nutrition 0.000 claims 2
• 238000002347 injection Methods 0.000 claims 2
• 239000007924 injection Substances 0.000 claims 2
• 229910001629 magnesium chloride Inorganic materials 0.000 claims 2
• 235000011147 magnesium chloride Nutrition 0.000 claims 2
• 229910000402 monopotassium phosphate Inorganic materials 0.000 claims 2
• 235000019796 monopotassium phosphate Nutrition 0.000 claims 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims 2
• PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims 2
• 239000001103 potassium chloride Substances 0.000 claims 2
• 235000011164 potassium chloride Nutrition 0.000 claims 2
• 238000002360 preparation method Methods 0.000 claims 2
• 235000002639 sodium chloride Nutrition 0.000 claims 2
• 238000013268 sustained release Methods 0.000 claims 2
• 239000012730 sustained-release form Substances 0.000 claims 2
• 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims 1
• 230000001575 pathological effect Effects 0.000 claims 1
• 230000002459 sustained effect Effects 0.000 claims 1
• 238000007910 systemic administration Methods 0.000 claims 1
• 238000002560 therapeutic procedure Methods 0.000 claims 1
• 230000003442 weekly effect Effects 0.000 claims 1